Eugene Gan

Ph.D.
Senior Director, Operations
Singapore Clinical Research Institute

Dr Eugene Gan joined the Singapore Clinical Research Institute (SCRI) in September 2021 as the Senior Director for Operations. In this role, Eugene leads both an operations team that support the conduct and running of public-funded clinical trials in Singapore, as well as a coordinating office that work with various partners to strategise and execute key initiatives aimed at enhancing Singapore’s clinical trials ecosystem.
Eugene previously spent 10 years at the Singapore Agency for Science, Technology and Research (A*STAR) where he held several roles. The most recent position was his appointment as the Deputy Chief Executive Officer of the Experimental Drug Development Centre (EDDC). In this role, Eugene led a scientific group of 70-plus scientists and research associates in more than 20 projects to discover and develop novel medicines against various human diseases. He was also in charge of the 20-plus EDDC Operations team that was responsible for the funding strategy, project management, innovation initiatives, and general day-to-day operations of the unit.
Prior to his appointment as Deputy CEO of EDDC, Eugene was the Chief Operating Officer (COO) of the Experimental Biotherapeutics Centre (EBC) from 2017 to 2018. Other appointments he had held at A*STAR included Business Development Manager at the Biomedical Sciences Industry Partnership Office (BMS IPO), Deputy Director Early Career Researchers Office (ECRO), and Deputy Director (PharmBio) BMRC. During his tenure at A*STAR, Eugene was principally involved in the creation of the National Healthcare Innovation Centre (NHIC) at MOH, the PharmBio Cluster (now the HBM cluster) at BMRC, the Therapeutics Development Review Grant (TDR) at BMRC, and the EBC at A*STAR. He also played a supporting role in the creation of the Research Support Centre (RSC) and several Industry Alignment Fund Pre-Positioning (IAF-PP) programmes.
Eugene was previously a Research Scientist at Eli Lilly & Company where he worked on several target validation and drug discovery projects. He graduated with a Bachelor of Science (with Honours) and Master of Science, both in Biochemistry from the Department of Chemistry at Indiana University in 1996 and 1999 respectively. He obtained his Doctor of Philosophy in Cancer Biology from the Department of Pharmacology and Cancer Biology at Duke University in 2007 studying the mechanisms of apoptosis in cancer.